SCHEMBL6944092

SCHEMBL6944092

CS(=O)(=O)c1ccc(Nc2c(C(=O)O)ccc(F)c2F)c(Cl)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 6/20 0.67
MAP2K2 P36507 3/20 0.54
LMNA P02545 1/20 0.50
PDK1 Q15118 1/20 0.46
PDK2 Q15119 1/20 0.46
PDK3 Q15120 1/20 0.46
PDK4 Q16654 1/20 0.46
AURKA O14965 1/20 0.46
TNFRSF1A P19438 1/20 0.46
KDR P35968 1/20 0.46
MAP3K9 P80192 1/20 0.46
PDE4B Q07343 1/20 0.43
RAF1 P04049 1/20 0.43
PDGFRB P09619 1/20 0.43
CSNK2A2 P19784 1/20 0.43
CSNK2B P67870 1/20 0.43
CSNK2A1 P68400 1/20 0.43
CSNK2A3 Q8NEV1 1/20 0.43
AURKC Q9UQB9 1/20 0.43
CAMK2A Q9UQM7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5989696 0.89 MAP2K1 (0.64) MAP2K1MAP2K2LMNAAURKATNFRSF1A
SCHEMBL6948319 0.88 MAP2K1 (0.51) MAP2K1MAP2K2LMNAPDK1PDK2
SCHEMBL6948280 0.87 MAP2K1 (0.55) MAP2K1MAP2K2LMNAAURKATNFRSF1A
SCHEMBL6951081 0.84 LMNA (0.48) MAP2K1LMNAPDK1PDK2PDK3
SCHEMBL22428819 0.83 MAP2K1 (0.73) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2
SCHEMBL1488147 0.80 MAP2K1 (0.73) MAP2K1MAP2K2LMNARAF1PDGFRB
Zapnometinib SCHEMBL1488782 0.80 MAP2K1 (1.00) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2
SCHEMBL29413453 0.80 MAP2K1 (0.73) MAP2K1MAP2K2LMNARAF1PDGFRB
Zapnometinib SCHEMBL30298104 0.80 MAP2K1 (1.00) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2
Zapnometinib SCHEMBL29362260 0.80 MAP2K1 (1.00) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1202724-B1 METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS WARNER LAMBERT CO (US) 2003-10-01 EP claimed
JP-2003504401-A 2003-02-04 JP claimed
EP-1202724-A2 METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-05-08 EP claimed
EP-1150950-A2 ANTHRANILIC ACID DERIVATIVES WARNER-LAMBERT COMPANY (US) 2001-11-07 EP claimed
WO-2001005393-A2 METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-01-25 WO claimed
WO-2000041505-A2 ANTHRANILIC ACID DERIVATIVES WARNER-LAMBERT COMPANY (US) 2000-07-20 WO claimed
EP-1202724-B1 METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS WARNER LAMBERT CO (US) 2003-10-01 EP disclosed
EP-1202724-A2 METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-05-08 EP disclosed
EP-1150950-A2 ANTHRANILIC ACID DERIVATIVES WARNER-LAMBERT COMPANY (US) 2001-11-07 EP disclosed
WO-2001005393-A2 METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-01-25 WO disclosed
WO-2000041505-A2 ANTHRANILIC ACID DERIVATIVES WARNER-LAMBERT COMPANY (US) 2000-07-20 WO disclosed